Pharmacokinetics of favipiravir during continuous venovenous haemofiltration in a critically ill patient with influenza

Laurent Ma Favié; Jean-Luc Murk; Adam Meijer; A Laura Nijstad; Erik M van Maarseveen; Maaike A Sikma

doi:10.3851/IMP3210

Pharmacokinetics of favipiravir during continuous venovenous haemofiltration in a critically ill patient with influenza

Laurent Ma Favié, Jean-Luc Murk, Adam Meijer, A Laura Nijstad, Erik M van Maarseveen, Maaike A Sikma

Research output: Contribution to journal › Article › peer-review

Abstract

Favipiravir is a novel antiviral drug approved for influenza treatment in Japan. Little is known about favipiravir pharmacokinetics in critically ill patients. Here, we report a patient with influenza treated with favipiravir and undergoing continuous venovenous haemofiltration (CVVH) on the Intensive Care Unit of a tertiary hospital in the Netherlands. Pharmacokinetic analyses showed increased clearance and decreased plasma levels compared to healthy volunteers. CVVH has no clinically relevant contribution to total clearance. Despite susceptibility to favipiravir, the influenza virus was not cleared. A multi-disciplinary approach is needed to ensure optimal favipiravir treatment in critically ill patients.

Original language	English
Pages (from-to)	457-461
Number of pages	5
Journal	Antiviral therapy
Volume	23
Issue number	5
DOIs	https://doi.org/10.3851/IMP3210
Publication status	Published - 2018
Externally published	Yes

Keywords

Amides/pharmacokinetics
Antiviral Agents/pharmacokinetics
Critical Illness
Fatal Outcome
Hemofiltration/methods
Humans
Influenza, Human/drug therapy
Intensive Care Units
Male
Middle Aged
Netherlands
Oseltamivir/administration & dosage
Pyrazines/pharmacokinetics
Tertiary Care Centers

Access to Document

10.3851/IMP3210

Cite this

@article{bd5ca3a46ddb455d9aca4df09751f4fa,

title = "Pharmacokinetics of favipiravir during continuous venovenous haemofiltration in a critically ill patient with influenza",

abstract = "Favipiravir is a novel antiviral drug approved for influenza treatment in Japan. Little is known about favipiravir pharmacokinetics in critically ill patients. Here, we report a patient with influenza treated with favipiravir and undergoing continuous venovenous haemofiltration (CVVH) on the Intensive Care Unit of a tertiary hospital in the Netherlands. Pharmacokinetic analyses showed increased clearance and decreased plasma levels compared to healthy volunteers. CVVH has no clinically relevant contribution to total clearance. Despite susceptibility to favipiravir, the influenza virus was not cleared. A multi-disciplinary approach is needed to ensure optimal favipiravir treatment in critically ill patients.",

keywords = "Amides/pharmacokinetics, Antiviral Agents/pharmacokinetics, Critical Illness, Fatal Outcome, Hemofiltration/methods, Humans, Influenza, Human/drug therapy, Intensive Care Units, Male, Middle Aged, Netherlands, Oseltamivir/administration & dosage, Pyrazines/pharmacokinetics, Tertiary Care Centers",

author = "Favi{\'e}, {Laurent Ma} and Jean-Luc Murk and Adam Meijer and Nijstad, {A Laura} and {van Maarseveen}, {Erik M} and Sikma, {Maaike A}",

year = "2018",

doi = "10.3851/IMP3210",

language = "English",

volume = "23",

pages = "457--461",

journal = "Antiviral therapy",

issn = "1359-6535",

publisher = "Sage Publications",

number = "5",

}

TY - JOUR

T1 - Pharmacokinetics of favipiravir during continuous venovenous haemofiltration in a critically ill patient with influenza

AU - Favié, Laurent Ma

AU - Murk, Jean-Luc

AU - Meijer, Adam

AU - Nijstad, A Laura

AU - van Maarseveen, Erik M

AU - Sikma, Maaike A

PY - 2018

Y1 - 2018

N2 - Favipiravir is a novel antiviral drug approved for influenza treatment in Japan. Little is known about favipiravir pharmacokinetics in critically ill patients. Here, we report a patient with influenza treated with favipiravir and undergoing continuous venovenous haemofiltration (CVVH) on the Intensive Care Unit of a tertiary hospital in the Netherlands. Pharmacokinetic analyses showed increased clearance and decreased plasma levels compared to healthy volunteers. CVVH has no clinically relevant contribution to total clearance. Despite susceptibility to favipiravir, the influenza virus was not cleared. A multi-disciplinary approach is needed to ensure optimal favipiravir treatment in critically ill patients.

AB - Favipiravir is a novel antiviral drug approved for influenza treatment in Japan. Little is known about favipiravir pharmacokinetics in critically ill patients. Here, we report a patient with influenza treated with favipiravir and undergoing continuous venovenous haemofiltration (CVVH) on the Intensive Care Unit of a tertiary hospital in the Netherlands. Pharmacokinetic analyses showed increased clearance and decreased plasma levels compared to healthy volunteers. CVVH has no clinically relevant contribution to total clearance. Despite susceptibility to favipiravir, the influenza virus was not cleared. A multi-disciplinary approach is needed to ensure optimal favipiravir treatment in critically ill patients.

KW - Amides/pharmacokinetics

KW - Antiviral Agents/pharmacokinetics

KW - Critical Illness

KW - Fatal Outcome

KW - Hemofiltration/methods

KW - Humans

KW - Influenza, Human/drug therapy

KW - Intensive Care Units

KW - Male

KW - Middle Aged

KW - Netherlands

KW - Oseltamivir/administration & dosage

KW - Pyrazines/pharmacokinetics

KW - Tertiary Care Centers

U2 - 10.3851/IMP3210

DO - 10.3851/IMP3210

M3 - Article

C2 - 29185991

SN - 1359-6535

VL - 23

SP - 457

EP - 461

JO - Antiviral therapy

JF - Antiviral therapy

IS - 5

ER -

Pharmacokinetics of favipiravir during continuous venovenous haemofiltration in a critically ill patient with influenza

Abstract

Keywords

Access to Document

Fingerprint

Cite this